Experienced in Idiopathic Pulmonary Fibrosis

Dr. Nirav Shah

Intensive Care Medicine
Office
110 S Paca St Fl 2, 
Baltimore, MD 
Experienced in Idiopathic Pulmonary Fibrosis
Office
110 S Paca St Fl 2, 
Baltimore, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Nirav Shah is an Intensive Care Medicine provider in Baltimore, Maryland. Dr. Shah is rated as an Experienced provider by MediFind in the treatment of Idiopathic Pulmonary Fibrosis. His top areas of expertise are Interstitial Lung Disease, Neurosarcoidosis, Acute Interstitial Pneumonia, Sarcoidosis, and Gastrostomy.

His clinical research consists of participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Intensive Care Medicine
Licenses
Critical Care Medicine in MD
Hospital Affiliations
University Of Maryland Medical Center
University Of MD Medical Center Midtown Campus
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Office
110 S Paca St Fl 2, Baltimore, MD 21201
Other Locations
University of Maryland Pediatric Associates PA
22 S Greene St, Baltimore, MD 21201

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
Enrollment Status: Active_not_recruiting
Publish Date: November 24, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
Prophylactic Topical Epinephrine to Reduce Transbronchial Lung Biopsy-related Hemorrhage in Lung Transplant Recipients: a Prospective Double-blind Placebo-controlled Trial (PROPHylactic Epinephrine in Transbronchial Biopsy [PROPHET] Trial)
Prophylactic Topical Epinephrine to Reduce Transbronchial Lung Biopsy-related Hemorrhage in Lung Transplant Recipients: a Prospective Double-blind Placebo-controlled Trial (PROPHylactic Epinephrine in Transbronchial Biopsy [PROPHET] Trial)
Enrollment Status: Completed
Publish Date: August 28, 2024
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
Enrollment Status: Completed
Publish Date: June 21, 2024
Intervention Type: Drug
Study Drug: Ontamalimab
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 307)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 307)
Enrollment Status: Terminated
Publish Date: March 31, 2022
Intervention Type: Drug, Other
Study Drug: Ontamalimab
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
Enrollment Status: Completed
Publish Date: January 14, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 301)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 301)
Enrollment Status: Terminated
Publish Date: June 14, 2021
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 305)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 305)
Enrollment Status: Terminated
Publish Date: April 29, 2021
Intervention Type: Other, Biological
Study Phase: Phase 3
View 8 Less Clinical Trials
Similar Doctors
Elite in Idiopathic Pulmonary Fibrosis
Dr. Steven D. Nathan
Pulmonary Medicine | Intensive Care Medicine
Elite in Idiopathic Pulmonary Fibrosis
Dr. Steven D. Nathan
Pulmonary Medicine | Intensive Care Medicine

Inova Health Care Services

3300 Gallows Rd, 
Falls Church, VA 
 (44.0 miles away)
703-776-4001
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Steven Nathan is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Falls Church, Virginia. Dr. Nathan is rated as an Elite provider by MediFind in the treatment of Idiopathic Pulmonary Fibrosis. His top areas of expertise are Idiopathic Pulmonary Fibrosis, Acute Interstitial Pneumonia, Interstitial Lung Disease, Lung Transplant, and Prostatectomy. Dr. Nathan is currently accepting new patients.

Elite in Idiopathic Pulmonary Fibrosis
Dr. Oksana Shlobin
Intensive Care Medicine
Elite in Idiopathic Pulmonary Fibrosis
Dr. Oksana Shlobin
Intensive Care Medicine

Inova Fairfax Medical Campus

3300 Gallows Rd, 
Falls Church, VA 
 (44.0 miles away)
703-776-2591
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Oksana Shlobin is an Intensive Care Medicine provider in Falls Church, Virginia. Dr. Shlobin is rated as an Elite provider by MediFind in the treatment of Idiopathic Pulmonary Fibrosis. Her top areas of expertise are Pulmonary Hypertension, Acute Interstitial Pneumonia, Interstitial Lung Disease, Lung Transplant, and Endoscopy.

Distinguished in Idiopathic Pulmonary Fibrosis
Dr. Shambhu Aryal
Intensive Care Medicine
Distinguished in Idiopathic Pulmonary Fibrosis
Dr. Shambhu Aryal
Intensive Care Medicine

Inova Fairfax Medical Campus

3300 Gallows Rd, 
Falls Church, VA 
 (44.0 miles away)
703-776-2986
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Shambhu Aryal is an Intensive Care Medicine provider in Falls Church, Virginia. Dr. Aryal is rated as a Distinguished provider by MediFind in the treatment of Idiopathic Pulmonary Fibrosis. His top areas of expertise are Acute Interstitial Pneumonia, Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis, and Lung Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Shah's expertise for a condition
ConditionClose
      View All 24 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile